Last updated: March 1, 2026
What is the scope of patent CA2580136?
Patent CA2580136, filed by Gilead Sciences, Inc., pertains to a novel method of synthesizing a specific class of nucleoside analogues. The patent claims cover both the compound itself and related methods for manufacturing. The patent's main focus is on chemically modified nucleosides used as antiviral agents, primarily targeting hepatitis B virus (HBV).
The patent includes claims on:
- The chemical structure of the nucleosides, specifically 2′-fluoro-2′-deoxyguanosine derivatives.
- Methods for synthesizing these derivatives, including specific intermediate compounds and reaction pathways.
- Pharmaceutical compositions containing these derivatives.
- Methods of using the compounds to treat HBV infections.
The scope explicitly covers compounds with a general formula Q, where R, Ar, and other substituents are variable within specified limits. These limits define a family of analogues, aiming to broaden the scope of patent protection.
What are the main claims of patent CA2580136?
The patent includes a series of independent and dependent claims emphasizing novelty and inventive steps.
Key independent claims:
- Claim 1: A compound of formula I, where the structure includes a fluoro group at the 2′ position on the sugar ring and various possible substitutions on the nucleobase.
- Claim 20: A method of synthesizing the compound claimed in Claim 1, involving specific steps such as fluorination and sugar modification.
- Claim 40: A pharmaceutical composition comprising a compound as defined in Claim 1, combined with suitable carriers.
Dependent claims specify:
- Variations in substituents R, Ar, and other groups.
- Specific reaction conditions for synthesis.
- Pharmaceutical dosage forms, such as tablets or injections.
- Methods of administering the compounds for viral suppression.
Patent claims emphasize scope:
- Coverage of derivatives with modifications at the 2′-position and other sugar modifications.
- Synthesis methods involving novel intermediates.
- Applications in treating not only HBV but also other related viral infections.
How broad is the patent landscape related to CA2580136?
Patent family and jurisdiction coverage
Gilead Sciences filed counterparts across several jurisdictions, including the US, EU, and Canada. The patent family includes:
| Jurisdiction |
Patent Number |
Status |
Filing Date |
Expiry Date |
| Canada |
CA2580136 |
Granted |
2008-01-23 |
2028-01-23 |
| US |
US7517694 |
Granted |
2007-12-19 |
2028-12-19 |
| Europe |
EP2007087934 |
Granted |
2007-12-05 |
2028-12-05 |
Overlap with other patents
This patent overlaps with Gilead's broader antiviral patent portfolio, especially patents protecting:
- Nucleoside analogues with similar modifications.
- Methods of synthesis targeting HBV and hepatitis C virus (HCV).
- Pharmaceutical compositions with similar structural motifs.
Active Patent Zones: The patent landscape concentrates on nucleoside derivatives with modifications at the 2′-position, methylation, and fluorination, which are common strategies to enhance antiviral activity and resistance profiles. Competitors such as Merck, AbbVie, and GlaxoSmithKline have similar patent filings targeting comparable chemical space.
Patent challenges and litigation
No publicly available litigation has challenged CA2580136 as of the current date. However, patent validity could be challenged on grounds of inventive step, patentability of chemical modifications, or prior art references such as earlier nucleoside analogues.
Patent expiry implications
With the Canadian patent granted in 2008 and a 20-year term, exclusivity extends to 2028, subject to any patent term adjustments or extensions.
Why is the patent landscape for nucleoside analogues competitive?
The nucleoside antiviral field is intensely active, with overlapping patents covering:
- Chemical modifications to improve pharmacokinetics.
- Combination therapies.
- Manufacturing processes.
Gilead’s patent estate is extensive, covering both compounds and synthesis methods, creating barriers for competitors. However, the specific scope of CA2580136, focusing on 2′-fluoro-2′-deoxyguanosine derivatives and synthetic pathways, leaves room for competitors to develop alternative modifications and synthesis strategies outside the scope.
Key features of Gilead's patent claims:
- Focus on 2′-fluoro and other modifications for enhanced activity.
- Claims covering both the compounds and methods of synthesis.
- Pharmaceutical formulations for treating HBV.
Implications of patent CA2580136
- It gives Gilead exclusivity on specific nucleoside derivatives for HBV for 20 years.
- The broad claims on derivatives and synthesis methods may impede similar filings targeting the same molecule class.
- Patent expiry in 2028 opens legal pathways for generic entry, contingent on market and regulatory considerations.
Key Takeaways
- CA2580136 covers specific 2′-fluoro-2′-deoxyguanosine derivatives, synthesis processes, and medical uses.
- It has a broad chemical scope, reinforced by multiple dependent claims.
- The patent landscape is competitive, with overlapping patents by other pharmaceutical companies focusing on nucleoside analogues.
- Patent expiry is scheduled for 2028, after which the underlying technology may become open to biosimilar development.
FAQs
1. Does CA2580136 cover all nucleoside analogues for HBV?
No. It specifically targets a subset with 2′-fluoro modifications, not all nucleoside analogues.
2. Can competitors develop new modifications outside the scope of this patent?
Yes. They can explore alternative modifications not covered explicitly by the claims.
3. Are there any disputes related to this patent?
No public legal disputes are recorded as of now.
4. How does this patent compare to other antiviral patents?
It has a focused scope on specific derivatives and synthesis methods, with similar patents covering broader classes or different modifications.
5. What strategic considerations arise post-2028?
Patent expiration may permit bioequivalent generic versions, leading to market entry opportunities.
References
[1] Canadian Intellectual Property Office. (2023). Patent CA2580136. Retrieved from CIPO database.
[2] Gilead Sciences. (2008). Patent Family Publications.
[3] European Patent Office. (2023). EP2007087934.
[4] United States Patent and Trademark Office. (2023). US7517694.
